Shihua Yang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shihua Yang has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Zifan Li
Department of Medical Oncology, Nanjing Lishui People’s Hospital, Nanjing, China
2 shared publications - Heng Wei
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China
1 shared publication Jian Gao
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China
1 shared publicationKexin Wu
Department of Rehabilitation, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China
1 shared publication- Li-Da Su
Neuroscience Care Unit, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China
1 shared publication Ningye Ma
Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, Liaoning 110004, China
1 shared publication
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 22779
Protein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors
- 21 July 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1) , 22779
Open AccessProtein corona guided albumin-binding paclitaxel nanoparticles for treatment of intracranial tumors
- Open Access
- 9 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1175
Integrating Microorganism-Based Therapy and Emerging Biotechnology in the Treatment of Intracranial Central Nervous System Diseases
The development of drug delivery systems for the treatment of intracranial central nervous system (CNS) diseases remains one of the most intractable medical problems in modern society, owing to the special physiological structure of the brain, including the existence of the blood-brain barrier (BBB), the CNS’s immune privilege, and its high complexity and vulnerability. Recently, a leading approach in the CNS drug delivery domain has been to employ or simulate the physiological behavior of microorganisms to overcome the BBB and remodel the pathological immune microenvironment in intracranial tissue. Considering the exceptional advancements in microorganism-based CNS drug delivery systems, it is imperative to review the latest breakthroughs. Herein, we summarize the emerging trends at the intersection of microorganism-based drug delivery systems and emerging biomedical technology for the treatment of CNS diseases, with a particular focus on preclinical research into microorganism-based drug delivery systems to combat CNS diseases, aiming to describe a credible landscape for further clinical trials.
- 9 September 2025
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (9) , 1175
Open AccessIntegrating Microorganism-Based Therapy and Emerging Biotechnology in the Treatment of Intracranial Central Nervous System Diseases
The development of drug delivery systems for the treatment of intracranial central nervous system (CNS) diseases remains one of the most intractable medical problems in modern society, owing to the special physiological structure of the brain, including the existence of the blood-brain barrier (BBB), the CNS’s immune privilege, and its high complexity and vulnerability. Recently, a leading approach in the CNS drug delivery domain has been to employ or simulate the physiological behavior of microorganisms to overcome the BBB and remodel the pathological immune microenvironment in intracranial tissue. Considering the exceptional advancements in microorganism-based CNS drug delivery systems, it is imperative to review the latest breakthroughs. Herein, we summarize the emerging trends at the intersection of microorganism-based drug delivery systems and emerging biomedical technology for the treatment of CNS diseases, with a particular focus on preclinical research into microorganism-based drug delivery systems to combat CNS diseases, aiming to describe a credible landscape for further clinical trials.
- Open Access
- 8 May 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113822
Formulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification
- 8 May 2025
- Published by Elsevier in Journal of Controlled Release
- Vol. 383, 113822
Open AccessFormulation-optimized oncolytic viruses: Advancing systemic delivery and immune amplification